Production (Stage)
MoonLake Immunotherapeutics
MLTX
$46.88
-$1.95-3.99%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 12.41% | -28.86% | -45.84% | -77.48% | -83.85% |
| Total Depreciation and Amortization | -70.95% | 3,904.00% | 15.66% | -91.43% | -8.99% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 765.55% | -114.98% | 7.82% | 34.44% | 7.82% |
| Change in Net Operating Assets | 90.54% | -147.09% | 255.65% | -87.04% | 55.68% |
| Cash from Operations | 21.32% | -91.79% | 9.38% | -86.58% | -21.09% |
| Capital Expenditure | 80.07% | -32.83% | -- | 100.00% | 25.51% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 138.25% | -351.92% | 166.57% | -206.88% | -124.41% |
| Cash from Investing | 138.18% | -352.79% | 166.42% | -204.62% | -124.65% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -33.64% | 65.06% | -- | -100.00% | 68.56% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -100.00% | -- | 100.00% | 43.26% |
| Cash from Financing | 48,421.57% | -17.70% | -- | -100.00% | 79.40% |
| Foreign Exchange rate Adjustments | -120.76% | 230.24% | -1,825.44% | -136.74% | -28.90% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 146.68% | -694.03% | 128.42% | -1,690.35% | -94.53% |